Hypofractionated radiotherapy with chemotherapy offers comparable survival, lower toxicity in LS-SCLC
A multi-center, randomized phase III trial has found that a three-week hypofractionated radiotherapy (HypoRT) schedule with concurrent chemotherapy provides similar survival outcomes and reduced toxicity compared to the standard ...
Sep 8, 2025
0
10



